A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102

Trial Profile

A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Pegzilarginase (Primary)
  • Indications Inborn error metabolic disorders
  • Focus Adverse reactions; Proof of concept
  • Sponsors Aeglea Biotherapeutics
  • Most Recent Events

    • 29 Nov 2017 According to an Aeglea Biotherapeutics medis release, first pediatric patient has been dosed.
    • 29 Nov 2017 According to an Aeglea Biotherapeutics medis release, protocol has been amended include pediatric dosing tiered by age beginning with patients aged 14 to 17, and continuing with patients aged 2 to 13.
    • 07 Nov 2017 According to an Aeglea BioTherapeutics media release, the company has initiated site selection and regulatory activities in Europe and site readiness in Canada to support its ex-US strategy for completion of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top